Combined treatment with anlotinib and chemotherapy for advanced esophageal squamous cell carcinoma improved patient survival: a case report

Dongyang Yang; Fei Xu; Xiaorong Lai; Ying Li; Huibing Gao; Ying Xu; Rongrong Chen; Dong Ma

Combined treatment with anlotinib and chemotherapy for advanced esophageal squamous cell carcinoma improved patient survival: a case report

Am J Transl Res. 2020 Oct 15;12(10):6578-6583. eCollection 2020.

Authors

Dongyang Yang¹, Fei Xu¹, Xiaorong Lai¹, Ying Li¹, Huibing Gao¹, Ying Xu², Rongrong Chen³, Dong Ma¹

Affiliations

¹ Department of Gastrointestinal Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences Guangzhou 510080, China.
² Department of Computer Science and Technology, School of Electronic and Information Engineering, Xi'an Jiaotong University Xi'an 710049, Shaanxi, China.
³ Geneplus-Beijing Ltd Beijing, China.

PMID: 33194054
PMCID: PMC7653628

Abstract

Esophageal squamous cell carcinoma (ESCC) is the predominant type of esophageal cancer in Eastern Asia. Historically, advanced ESCC treatments have had low efficacy and new treatments, including immunotherapy or combination therapies, are emerging. Here, we report a special case of recurrent ESCC after surgery. The patient had a failed immunotherapy course, but benefited from anlotinib combined with chemotherapy for a fourth-line therapy. Survival after the combined therapy was greater than 19 months, and the overall patient survival was greater than 32 months.

Keywords: Esophageal squamous cell carcinoma; anlotinib; chemotherapy.